Person:
ÇELİK, BURAK

Loading...
Profile Picture
Status
Organizational Units
Job Title
First Name
BURAK
Last Name
ÇELİK
Name
Email Address
Birth Date

Search Results

Now showing 1 - 6 of 6
No Thumbnail Available
PublicationMetadata only

Apolipoprotein E4 Mediated Targeting of Blood Brain Barrier Using Nano-Micellar Metal Chelators for Treatment of Alzheimer’s Disease

2015-08-06, BAHADORİ, FATEMEH, ÇELİK, BURAK, Kazdal, Fatma, KUŞMAN, TUBA, BAHADORİ, FATEMEH, ÇELİK, BURAK, KUŞMAN, TUBA

No Thumbnail Available
PublicationMetadata only

Plant extracts as metal chelators for treatment of Alzheimer’s disease

2015-08-06, Kazdal, Fatma, ÇELİK, BURAK, BAHADORİ, FATEMEH, Ertaş, Abdulselam, ÇELİK, BURAK, BAHADORİ, FATEMEH

No Thumbnail Available
PublicationMetadata only

Hedeflendirilmiş Nanoilaçlar

2017-09-01, ÖNYÜKSEL, Hayat, BAHADORİ, FATEMEH, ÇELİK, BURAK, BAHADORİ, FATEMEH, ÇELİK, BURAK

No Thumbnail Available
PublicationMetadata only

A Novel Nano Formulation For Synthetic And Plant Based Metal Chelators With Blood-Brain Barrier Targeting Property For Treatment Of Alzheimer’s Disease

2015-06-12, BAHADORİ, FATEMEH, Kazdal, Fatma, ÇELİK, BURAK, BAHADORİ, FATEMEH, ÇELİK, BURAK

Loading...
Thumbnail Image
PublicationOpen Access

Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials

2020-04-30T00:00:00Z, Eskandari, Zahra, BAHADORİ, FATEMEH, ÇELİK, BURAK, Onyuksel, Hayat, BAHADORİ, FATEMEH, ÇELİK, BURAK

Traditional systemic chemotherapy involves the wide distribution of drug molecules in the body, causing toxic side effects in the healthy tissues and limiting the therapeutic dose required at the site of drug action. In order to decrease side effects and increase the drug efficacy, recent research on chemotherapy focuses on drug targeting. Targeted therapy can be achieved by several mechanisms including; 1) using an antibody as a drug that is specific to a disease biomarker, 2) using an antibody (or peptide) as a targeting agent conjugated to the drug molecule, 3) delivering the drug molecules to the target tissue in a nano-carrier with or without the targeting agent attached on its surface. The third approach involves the nanomedicines that can be targeted to diseased tissues by both passive (extravasating at diseased sites due to leaky vasculature) and active (specific interaction of the targeting agent with disease biomarker) targeting mechanisms. In this review we will cover the passively targeted nanomedicines prepared using nano drug carriers. Ideally the carrier particle should be in the right size (1-100nm), stable enough to prevent drug leakage during circulation, and safe not to cause any damage to healthy tissues. Competition for all these properties generated many different types of materials to be used as nanodrug delivery systems. After a brief review of most commonly used drug carriers, we discuss the clinical use of the targeted nanomedicines with regard to their pharmacokinetic and pharmacodynamics properties, and how these properties vary from conventional formulations providing free drugs in the circulation after administration.

No Thumbnail Available
PublicationMetadata only

In-vitro investigation of changes in efficacy and toxicity of nano-paclitaxel during co-applications with antioxidant natural compounds

2018-05-08, Kazdal, Fatma, BAHADORİ, FATEMEH, Eskandari, Zahra, KOÇYİĞİT, ABDÜRRAHİM, Şahin, Vildan Betül, Öz Öztenekeci, Burcu, ÇELİK, BURAK, BAHADORİ, FATEMEH, KOÇYİĞİT, ABDÜRRAHİM, ÇELİK, BURAK